 | • レポートコード：MRC2Q12-16777 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、128ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、HIV抗レトロウイルス薬のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 HIV抗レトロウイルス薬のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 HIV抗レトロウイルス薬の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 HIV抗レトロウイルス薬のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのHIV抗レトロウイルス薬の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のHIV抗レトロウイルス薬の売上および2028年までの予測に焦点を当てています。 HIV抗レトロウイルス薬のグローバル主要企業には、ViiV Healthcare(GlaxoSmithKline)、Gilead Sciences、AbbVie Inc.、Merck & Co、GSK、Bristol-Myers Squibb Company、Theratechnologies Inc.、Roche Holding AG、Teva Pharmaceuticals、Pfizer、Frontier Biotechnologies、Shionogi、Julphar Bangladesh、Mylan Pharmaceuticals Inc.、Genentech, Inc.、Boehringer Ingelheim、Cipla、MSD、Abbott、Johnson & Johnson、Biocon Limited、Affine Formulations Limited、IPCA Laboratories、Natco Pharma、Beacon Pharmaceuticalsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 HIV抗レトロウイルス薬市場は、タイプとアプリケーションによって区分されます。世界のHIV抗レトロウイルス薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 ヌクレオシド逆転写酵素阻害剤、非ヌクレオシド逆転写酵素阻害剤、プロテアーゼ阻害剤、融合阻害剤、その他 【アプリケーション別セグメント】 病院薬局、小売薬局、オンライン薬局 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - HIV抗レトロウイルス薬製品概要 - タイプ別市場（ヌクレオシド逆転写酵素阻害剤、非ヌクレオシド逆転写酵素阻害剤、プロテアーゼ阻害剤、融合阻害剤、その他） - アプリケーション別市場（病院薬局、小売薬局、オンライン薬局） - 調査の目的 ・エグゼクティブサマリー - 世界のHIV抗レトロウイルス薬販売量予測2017-2028 - 世界のHIV抗レトロウイルス薬売上予測2017-2028 - HIV抗レトロウイルス薬の地域別販売量 - HIV抗レトロウイルス薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別HIV抗レトロウイルス薬販売量 - 主要メーカー別HIV抗レトロウイルス薬売上 - 主要メーカー別HIV抗レトロウイルス薬価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（ヌクレオシド逆転写酵素阻害剤、非ヌクレオシド逆転写酵素阻害剤、プロテアーゼ阻害剤、融合阻害剤、その他） - HIV抗レトロウイルス薬のタイプ別販売量 - HIV抗レトロウイルス薬のタイプ別売上 - HIV抗レトロウイルス薬のタイプ別価格 ・アプリケーション別市場規模（病院薬局、小売薬局、オンライン薬局） - HIV抗レトロウイルス薬のアプリケーション別販売量 - HIV抗レトロウイルス薬のアプリケーション別売上 - HIV抗レトロウイルス薬のアプリケーション別価格 ・北米市場 - 北米のHIV抗レトロウイルス薬市場規模（タイプ別、アプリケーション別） - 主要国別のHIV抗レトロウイルス薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのHIV抗レトロウイルス薬市場規模（タイプ別、アプリケーション別） - 主要国別のHIV抗レトロウイルス薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のHIV抗レトロウイルス薬市場規模（タイプ別、アプリケーション別） - 主要国別のHIV抗レトロウイルス薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のHIV抗レトロウイルス薬市場規模（タイプ別、アプリケーション別） - 主要国別のHIV抗レトロウイルス薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのHIV抗レトロウイルス薬市場規模（タイプ別、アプリケーション別） - 主要国別のHIV抗レトロウイルス薬市場規模（トルコ、サウジアラビア） ・企業情報 ViiV Healthcare(GlaxoSmithKline)、Gilead Sciences、AbbVie Inc.、Merck & Co、GSK、Bristol-Myers Squibb Company、Theratechnologies Inc.、Roche Holding AG、Teva Pharmaceuticals、Pfizer、Frontier Biotechnologies、Shionogi、Julphar Bangladesh、Mylan Pharmaceuticals Inc.、Genentech, Inc.、Boehringer Ingelheim、Cipla、MSD、Abbott、Johnson & Johnson、Biocon Limited、Affine Formulations Limited、IPCA Laboratories、Natco Pharma、Beacon Pharmaceuticals ・産業チェーン及び販売チャネル分析 - HIV抗レトロウイルス薬の産業チェーン分析 - HIV抗レトロウイルス薬の原材料 - HIV抗レトロウイルス薬の生産プロセス - HIV抗レトロウイルス薬の販売及びマーケティング - HIV抗レトロウイルス薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - HIV抗レトロウイルス薬の産業動向 - HIV抗レトロウイルス薬のマーケットドライバー - HIV抗レトロウイルス薬の課題 - HIV抗レトロウイルス薬の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for HIV Antiretroviral Drug estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for HIV Antiretroviral Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for HIV Antiretroviral Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for HIV Antiretroviral Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of HIV Antiretroviral Drug include ViiV Healthcare(GlaxoSmithKline), Gilead Sciences, AbbVie Inc., Merck & Co, GSK, Bristol-Myers Squibb Company, Theratechnologies Inc., Roche Holding AG and Teva Pharmaceuticals, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the HIV Antiretroviral Drug companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional HIV Antiretroviral Drug market. Further, it explains the major drivers and regional dynamics of the global HIV Antiretroviral Drug market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
ViiV Healthcare(GlaxoSmithKline)
Gilead Sciences
AbbVie Inc.
Merck & Co
GSK
Bristol-Myers Squibb Company
Theratechnologies Inc.
Roche Holding AG
Teva Pharmaceuticals
Pfizer
Frontier Biotechnologies
Shionogi
Julphar Bangladesh
Mylan Pharmaceuticals Inc.
Genentech, Inc.
Boehringer Ingelheim
Cipla
MSD
Abbott
Johnson & Johnson
Biocon Limited
Affine Formulations Limited
IPCA Laboratories
Natco Pharma
Beacon Pharmaceuticals
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
HIV Antiretroviral Drug Segment by Type
Nucleoside Reverse Transcriptase Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors
Protease Inhibitors
Fusion Inhibitors
Others
HIV Antiretroviral Drug Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the HIV Antiretroviral Drug market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for HIV Antiretroviral Drug market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of HIV Antiretroviral Drug, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for HIV Antiretroviral Drug, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the HIV Antiretroviral Drug revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global HIV Antiretroviral Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for HIV Antiretroviral Drug revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including ViiV Healthcare(GlaxoSmithKline), Gilead Sciences, AbbVie Inc., Merck & Co, GSK, Bristol-Myers Squibb Company, Theratechnologies Inc., Roche Holding AG and Teva Pharmaceuticals, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of HIV Antiretroviral Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of HIV Antiretroviral Drug companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, HIV Antiretroviral Drug revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global HIV Antiretroviral Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Nucleoside Reverse Transcriptase Inhibitors
1.2.3 Non-Nucleoside Reverse Transcriptase Inhibitors
1.2.4 Protease Inhibitors
1.2.5 Fusion Inhibitors
1.2.6 Others
1.3 Market by Application
1.3.1 Global HIV Antiretroviral Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global HIV Antiretroviral Drug Market Perspective (2017-2028)
2.2 HIV Antiretroviral Drug Growth Trends by Region
2.2.1 HIV Antiretroviral Drug Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 HIV Antiretroviral Drug Historic Market Size by Region (2017-2022)
2.2.3 HIV Antiretroviral Drug Forecasted Market Size by Region (2023-2028)
2.3 HIV Antiretroviral Drug Market Dynamics
2.3.1 HIV Antiretroviral Drug Industry Trends
2.3.2 HIV Antiretroviral Drug Market Drivers
2.3.3 HIV Antiretroviral Drug Market Challenges
2.3.4 HIV Antiretroviral Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top HIV Antiretroviral Drug Players by Revenue
3.1.1 Global Top HIV Antiretroviral Drug Players by Revenue (2017-2022)
3.1.2 Global HIV Antiretroviral Drug Revenue Market Share by Players (2017-2022)
3.2 Global HIV Antiretroviral Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by HIV Antiretroviral Drug Revenue
3.4 Global HIV Antiretroviral Drug Market Concentration Ratio
3.4.1 Global HIV Antiretroviral Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by HIV Antiretroviral Drug Revenue in 2021
3.5 HIV Antiretroviral Drug Key Players Head office and Area Served
3.6 Key Players HIV Antiretroviral Drug Product Solution and Service
3.7 Date of Enter into HIV Antiretroviral Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 HIV Antiretroviral Drug Breakdown Data by Type
4.1 Global HIV Antiretroviral Drug Historic Market Size by Type (2017-2022)
4.2 Global HIV Antiretroviral Drug Forecasted Market Size by Type (2023-2028)
5 HIV Antiretroviral Drug Breakdown Data by Application
5.1 Global HIV Antiretroviral Drug Historic Market Size by Application (2017-2022)
5.2 Global HIV Antiretroviral Drug Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America HIV Antiretroviral Drug Market Size (2017-2028)
6.2 North America HIV Antiretroviral Drug Market Size by Type
6.2.1 North America HIV Antiretroviral Drug Market Size by Type (2017-2022)
6.2.2 North America HIV Antiretroviral Drug Market Size by Type (2023-2028)
6.2.3 North America HIV Antiretroviral Drug Market Share by Type (2017-2028)
6.3 North America HIV Antiretroviral Drug Market Size by Application
6.3.1 North America HIV Antiretroviral Drug Market Size by Application (2017-2022)
6.3.2 North America HIV Antiretroviral Drug Market Size by Application (2023-2028)
6.3.3 North America HIV Antiretroviral Drug Market Share by Application (2017-2028)
6.4 North America HIV Antiretroviral Drug Market Size by Country
6.4.1 North America HIV Antiretroviral Drug Market Size by Country (2017-2022)
6.4.2 North America HIV Antiretroviral Drug Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe HIV Antiretroviral Drug Market Size (2017-2028)
7.2 Europe HIV Antiretroviral Drug Market Size by Type
7.2.1 Europe HIV Antiretroviral Drug Market Size by Type (2017-2022)
7.2.2 Europe HIV Antiretroviral Drug Market Size by Type (2023-2028)
7.2.3 Europe HIV Antiretroviral Drug Market Share by Type (2017-2028)
7.3 Europe HIV Antiretroviral Drug Market Size by Application
7.3.1 Europe HIV Antiretroviral Drug Market Size by Application (2017-2022)
7.3.2 Europe HIV Antiretroviral Drug Market Size by Application (2023-2028)
7.3.3 Europe HIV Antiretroviral Drug Market Share by Application (2017-2028)
7.4 Europe HIV Antiretroviral Drug Market Size by Country
7.4.1 Europe HIV Antiretroviral Drug Market Size by Country (2017-2022)
7.4.2 Europe HIV Antiretroviral Drug Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific HIV Antiretroviral Drug Market Size (2017-2028)
8.2 Asia-Pacific HIV Antiretroviral Drug Market Size by Type
8.2.1 Asia-Pacific HIV Antiretroviral Drug Market Size by Type (2017-2022)
8.2.2 Asia-Pacific HIV Antiretroviral Drug Market Size by Type (2023-2028)
8.2.3 Asia-Pacific HIV Antiretroviral Drug Market Share by Type (2017-2028)
8.3 Asia-Pacific HIV Antiretroviral Drug Market Size by Application
8.3.1 Asia-Pacific HIV Antiretroviral Drug Market Size by Application (2017-2022)
8.3.2 Asia-Pacific HIV Antiretroviral Drug Market Size by Application (2023-2028)
8.3.3 Asia-Pacific HIV Antiretroviral Drug Market Share by Application (2017-2028)
8.4 Asia-Pacific HIV Antiretroviral Drug Market Size by Region
8.4.1 Asia-Pacific HIV Antiretroviral Drug Market Size by Region (2017-2022)
8.4.2 Asia-Pacific HIV Antiretroviral Drug Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America HIV Antiretroviral Drug Market Size (2017-2028)
9.2 Latin America HIV Antiretroviral Drug Market Size by Type
9.2.1 Latin America HIV Antiretroviral Drug Market Size by Type (2017-2022)
9.2.2 Latin America HIV Antiretroviral Drug Market Size by Type (2023-2028)
9.2.3 Latin America HIV Antiretroviral Drug Market Share by Type (2017-2028)
9.3 Latin America HIV Antiretroviral Drug Market Size by Application
9.3.1 Latin America HIV Antiretroviral Drug Market Size by Application (2017-2022)
9.3.2 Latin America HIV Antiretroviral Drug Market Size by Application (2023-2028)
9.3.3 Latin America HIV Antiretroviral Drug Market Share by Application (2017-2028)
9.4 Latin America HIV Antiretroviral Drug Market Size by Country
9.4.1 Latin America HIV Antiretroviral Drug Market Size by Country (2017-2022)
9.4.2 Latin America HIV Antiretroviral Drug Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa HIV Antiretroviral Drug Market Size (2017-2028)
10.2 Middle East & Africa HIV Antiretroviral Drug Market Size by Type
10.2.1 Middle East & Africa HIV Antiretroviral Drug Market Size by Type (2017-2022)
10.2.2 Middle East & Africa HIV Antiretroviral Drug Market Size by Type (2023-2028)
10.2.3 Middle East & Africa HIV Antiretroviral Drug Market Share by Type (2017-2028)
10.3 Middle East & Africa HIV Antiretroviral Drug Market Size by Application
10.3.1 Middle East & Africa HIV Antiretroviral Drug Market Size by Application (2017-2022)
10.3.2 Middle East & Africa HIV Antiretroviral Drug Market Size by Application (2023-2028)
10.3.3 Middle East & Africa HIV Antiretroviral Drug Market Share by Application (2017-2028)
10.4 Middle East & Africa HIV Antiretroviral Drug Market Size by Country
10.4.1 Middle East & Africa HIV Antiretroviral Drug Market Size by Country (2017-2022)
10.4.2 Middle East & Africa HIV Antiretroviral Drug Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 ViiV Healthcare(GlaxoSmithKline)
11.1.1 ViiV Healthcare(GlaxoSmithKline) Company Details
11.1.2 ViiV Healthcare(GlaxoSmithKline) Business Overview
11.1.3 ViiV Healthcare(GlaxoSmithKline) HIV Antiretroviral Drug Introduction
11.1.4 ViiV Healthcare(GlaxoSmithKline) Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.1.5 ViiV Healthcare(GlaxoSmithKline) Recent Developments
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Details
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences HIV Antiretroviral Drug Introduction
11.2.4 Gilead Sciences Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.2.5 Gilead Sciences Recent Developments
11.3 AbbVie Inc.
11.3.1 AbbVie Inc. Company Details
11.3.2 AbbVie Inc. Business Overview
11.3.3 AbbVie Inc. HIV Antiretroviral Drug Introduction
11.3.4 AbbVie Inc. Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.3.5 AbbVie Inc. Recent Developments
11.4 Merck & Co
11.4.1 Merck & Co Company Details
11.4.2 Merck & Co Business Overview
11.4.3 Merck & Co HIV Antiretroviral Drug Introduction
11.4.4 Merck & Co Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.4.5 Merck & Co Recent Developments
11.5 GSK
11.5.1 GSK Company Details
11.5.2 GSK Business Overview
11.5.3 GSK HIV Antiretroviral Drug Introduction
11.5.4 GSK Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.5.5 GSK Recent Developments
11.6 Bristol-Myers Squibb Company
11.6.1 Bristol-Myers Squibb Company Company Details
11.6.2 Bristol-Myers Squibb Company Business Overview
11.6.3 Bristol-Myers Squibb Company HIV Antiretroviral Drug Introduction
11.6.4 Bristol-Myers Squibb Company Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.6.5 Bristol-Myers Squibb Company Recent Developments
11.7 Theratechnologies Inc.
11.7.1 Theratechnologies Inc. Company Details
11.7.2 Theratechnologies Inc. Business Overview
11.7.3 Theratechnologies Inc. HIV Antiretroviral Drug Introduction
11.7.4 Theratechnologies Inc. Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.7.5 Theratechnologies Inc. Recent Developments
11.8 Roche Holding AG
11.8.1 Roche Holding AG Company Details
11.8.2 Roche Holding AG Business Overview
11.8.3 Roche Holding AG HIV Antiretroviral Drug Introduction
11.8.4 Roche Holding AG Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.8.5 Roche Holding AG Recent Developments
11.9 Teva Pharmaceuticals
11.9.1 Teva Pharmaceuticals Company Details
11.9.2 Teva Pharmaceuticals Business Overview
11.9.3 Teva Pharmaceuticals HIV Antiretroviral Drug Introduction
11.9.4 Teva Pharmaceuticals Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.9.5 Teva Pharmaceuticals Recent Developments
11.10 Pfizer
11.10.1 Pfizer Company Details
11.10.2 Pfizer Business Overview
11.10.3 Pfizer HIV Antiretroviral Drug Introduction
11.10.4 Pfizer Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.10.5 Pfizer Recent Developments
11.11 Frontier Biotechnologies
11.11.1 Frontier Biotechnologies Company Details
11.11.2 Frontier Biotechnologies Business Overview
11.11.3 Frontier Biotechnologies HIV Antiretroviral Drug Introduction
11.11.4 Frontier Biotechnologies Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.11.5 Frontier Biotechnologies Recent Developments
11.12 Shionogi
11.12.1 Shionogi Company Details
11.12.2 Shionogi Business Overview
11.12.3 Shionogi HIV Antiretroviral Drug Introduction
11.12.4 Shionogi Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.12.5 Shionogi Recent Developments
11.13 Julphar Bangladesh
11.13.1 Julphar Bangladesh Company Details
11.13.2 Julphar Bangladesh Business Overview
11.13.3 Julphar Bangladesh HIV Antiretroviral Drug Introduction
11.13.4 Julphar Bangladesh Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.13.5 Julphar Bangladesh Recent Developments
11.14 Mylan Pharmaceuticals Inc.
11.14.1 Mylan Pharmaceuticals Inc. Company Details
11.14.2 Mylan Pharmaceuticals Inc. Business Overview
11.14.3 Mylan Pharmaceuticals Inc. HIV Antiretroviral Drug Introduction
11.14.4 Mylan Pharmaceuticals Inc. Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.14.5 Mylan Pharmaceuticals Inc. Recent Developments
11.15 Genentech, Inc.
11.15.1 Genentech, Inc. Company Details
11.15.2 Genentech, Inc. Business Overview
11.15.3 Genentech, Inc. HIV Antiretroviral Drug Introduction
11.15.4 Genentech, Inc. Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.15.5 Genentech, Inc. Recent Developments
11.16 Boehringer Ingelheim
11.16.1 Boehringer Ingelheim Company Details
11.16.2 Boehringer Ingelheim Business Overview
11.16.3 Boehringer Ingelheim HIV Antiretroviral Drug Introduction
11.16.4 Boehringer Ingelheim Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.16.5 Boehringer Ingelheim Recent Developments
11.17 Cipla
11.17.1 Cipla Company Details
11.17.2 Cipla Business Overview
11.17.3 Cipla HIV Antiretroviral Drug Introduction
11.17.4 Cipla Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.17.5 Cipla Recent Developments
11.18 MSD
11.18.1 MSD Company Details
11.18.2 MSD Business Overview
11.18.3 MSD HIV Antiretroviral Drug Introduction
11.18.4 MSD Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.18.5 MSD Recent Developments
11.19 Abbott
11.19.1 Abbott Company Details
11.19.2 Abbott Business Overview
11.19.3 Abbott HIV Antiretroviral Drug Introduction
11.19.4 Abbott Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.19.5 Abbott Recent Developments
11.20 Johnson & Johnson
11.20.1 Johnson & Johnson Company Details
11.20.2 Johnson & Johnson Business Overview
11.20.3 Johnson & Johnson HIV Antiretroviral Drug Introduction
11.20.4 Johnson & Johnson Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.20.5 Johnson & Johnson Recent Developments
11.21 Biocon Limited
11.21.1 Biocon Limited Company Details
11.21.2 Biocon Limited Business Overview
11.21.3 Biocon Limited HIV Antiretroviral Drug Introduction
11.21.4 Biocon Limited Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.21.5 Biocon Limited Recent Developments
11.22 Affine Formulations Limited
11.22.1 Affine Formulations Limited Company Details
11.22.2 Affine Formulations Limited Business Overview
11.22.3 Affine Formulations Limited HIV Antiretroviral Drug Introduction
11.22.4 Affine Formulations Limited Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.22.5 Affine Formulations Limited Recent Developments
11.23 IPCA Laboratories
11.23.1 IPCA Laboratories Company Details
11.23.2 IPCA Laboratories Business Overview
11.23.3 IPCA Laboratories HIV Antiretroviral Drug Introduction
11.23.4 IPCA Laboratories Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.23.5 IPCA Laboratories Recent Developments
11.24 Natco Pharma
11.24.1 Natco Pharma Company Details
11.24.2 Natco Pharma Business Overview
11.24.3 Natco Pharma HIV Antiretroviral Drug Introduction
11.24.4 Natco Pharma Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.24.5 Natco Pharma Recent Developments
11.25 Beacon Pharmaceuticals
11.25.1 Beacon Pharmaceuticals Company Details
11.25.2 Beacon Pharmaceuticals Business Overview
11.25.3 Beacon Pharmaceuticals HIV Antiretroviral Drug Introduction
11.25.4 Beacon Pharmaceuticals Revenue in HIV Antiretroviral Drug Business (2017-2022)
11.25.5 Beacon Pharmaceuticals Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer